Educate Why Aduhelm Isn’t a Miracle for Alzheimer’s

August 2021

You’ll hear controversy about Aduhelm (aducanumab), the first new med for Alzheimer’s disease in almost 20 years.

It’s a monoclonal antibody given as an IV infusion every 4 weeks.

Patients with Alzheimer’s and their families are often looking for a glimmer of hope.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote